Internal Medicine, Hematology & Oncology · Hinsdale, IL
NPI
1467646141
Since 2007
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
950 N York Rd Ste 201a
Hinsdale, IL, 60521
Phone (630) 560-0121
Groups this clinician bills Medicare through
Medicare paid, 2024
$974K
71,154 services
Medicare patients, 2024
181
Average age 75
Drug cost, 2024
$1.4M
446 prescriptions
Company payments, 2025
$3,631
From 48 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Srilata Gundala was code J1437 (injection, ferric derisomaltose, 10 mg), 2,702 times for 22 patients. In total Srilata Gundala billed 71,154 services in 96 codes, and Medicare paid $974K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-04-15.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 2,702 | 22 | $15.78 | $43K |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 901 | 12 | $0.67 | $606 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 701 | 12 | $0.09 | $63.18 |
| 99214 Office E&M - Established | Office | 246 | 111 | $94.70 | $23K |
| 99457 E&M - Miscellaneous | Office | 230 | 29 | $38.08 | $8,759 |
| 99454 E&M - Miscellaneous | Office | 183 | 24 | $37.30 | $6,827 |
| 96372 Injection Administration | Office | 179 | 22 | $11.29 | $2,021 |
| 96367 Intravenous Infusion, Hydration | Office | 156 | 15 | $23.08 | $3,600 |
| 96365 Intravenous Infusion, Hydration | Office | 105 | 31 | $51.10 | $5,365 |
| 96413 Chemotherapy Administration | Office | 101 | 17 | $106.35 | $11K |
| 96368 Intravenous Infusion, Hydration | Office | 80 | 13 | $16.02 | $1,282 |
| 99215 Office E&M - Established | Office | 66 | 27 | $144.01 | $9,505 |
| 99223 Hospital E&M - Initial | Facility | 50 | 31 | $140.72 | $7,036 |
| 99232 Hospital E&M - Subsequent | Facility | 48 | 15 | $63.93 | $3,069 |
| 99213 Office E&M - Established | Office | 33 | 29 | $58.15 | $1,919 |
By year: 2022 $503K for 39,763 services; 2023 $388K for 25,742 services; 2024 $974K for 71,154 services.
Medicare prescription drug claims, 2024
In 2024, the drug Srilata Gundala prescribed most often to Medicare patients was Anastrozole, with 75 prescriptions and refills. In total Srilata Gundala wrote 446 Medicare prescriptions that cost $1.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 75 | 189 | 19 | $1,092 |
| Lenalidomide Generic | 24 | 24 | Under 11 | $321K |
| Ondansetron Odt Ondansetron | 22 | 22 | 17 | $782 |
| Valacyclovir Valacyclovir Hcl | 19 | 31 | Under 11 | $282 |
| Prochlorperazine Maleate Generic | 18 | 18 | 12 | $405 |
| Venclexta Venetoclax | 15 | 15 | Under 11 | $38K |
| Exemestane Generic | 15 | 32 | Under 11 | $1,111 |
| Darzalex Daratumumab | 15 | 15 | Under 11 | $211K |
| Gabapentin Generic | 14 | 20 | Under 11 | $82.2 |
| Prolia Denosumab | 11 | 66 | Under 11 | $18K |
| Acyclovir Generic | 11 | 11 | Under 11 | $68.09 |
Brand drugs: 155 claims; generic drugs: 291 claims; opioid claims: 13.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Srilata Gundala $3,631 ($3,631 in general payments such as food, travel and fees) from 48 companies. The largest payer was Novartis Pharmaceuticals Corporation with $1,082.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 19 | $1,082 |
| Janssen Biotech, Inc. JNJ | 9 | $261 |
| AstraZeneca Pharmaceuticals LP AZN | 9 | $192 |
| Abbvie Inc. ABBV | 9 | $188 |
| Daiichi Sankyo Inc. 4568.T | 4 | $181 |
| Pfizer Inc. PFE | 6 | $155 |
| Gilead Sciences, Inc. GILD | 1 | $132 |
| Celgene Corporation BMY | 5 | $117 |
| Amneal Pharmaceuticals LLC AMRX | 3 | $81.8 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 3 | $80.32 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.